Back to Search Start Over

Transcatheter embolization of hepatocellular carcinoma with epirubicin-loaded DC beads in Chinese patients.

Authors :
Zhou GH
Sun JH
Zhang YL
Zhou TY
Nie CH
Zhu TY
Ai J
Chen SQ
Wang BQ
Yu ZN
Wang HL
Wu LM
Chen LM
Zheng SS
Source :
Translational cancer research [Transl Cancer Res] 2019 Feb; Vol. 8 (1), pp. 279-289.
Publication Year :
2019

Abstract

Background: This study evaluated the safety and efficacy of transcatheter chemoembolization with drug eluting beads (DEB-TACE) and compared it to the conventional TACE (cTACE) therapy method for hepatocellular carcinoma (HCC) in Chinese patients.<br />Methods: Seventy-four patients were treated with DEB-TACE using the DC bead, and 80 patients were treated with cTACE for HCC. The modified response evaluation criteria in solid tumors (mRECIST) criteria were used to evaluate clinical response, with adverse events assessed according to the Common Terminology Criteria for Adverse Events (CTCAE).<br />Results: Post-TACE, 9 patients (12.2%) achieved complete response (CR) and 44 (59.5%) achieved partial response (PR), with an overall tumor response rate (ORR) of 71.6% in the DEB-TACE group. Twelve patients (15%) achieved CR, and 38 (47.5%) achieved PR, with an ORR of 62.5% in the cTACE group. However, there was no significant difference in ORR between the two groups (P=0.229). Univariate logistic regression analysis determined that more than 3 nodules, higher Barcelona clinic liver cancer (BCLC) stage, portal vein invasion, previous chemotherapy (cTACE), and previous surgery were correlated with a worse ORR. Most common adverse events were not severe.<br />Conclusions: DEB-TACE by DC bead was efficient and well-tolerated compared to cTACE in Chinese HCC patients. However, the present study showed no significant difference in ORR between the DEB-TACE and cTACE in the patient group with HCC. The BCLC stage, number of nodules, portal vein invasion, cTACE, and surgery history could possibly be a predictive factor for HCC treatment response.<br />Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.01.36). The authors have no conflicts of interest to declare.<br /> (2019 Translational Cancer Research. All rights reserved.)

Details

Language :
English
ISSN :
2219-6803
Volume :
8
Issue :
1
Database :
MEDLINE
Journal :
Translational cancer research
Publication Type :
Academic Journal
Accession number :
35116757
Full Text :
https://doi.org/10.21037/tcr.2019.01.36